Selected article for: "acute respiratory and admission dimer"
Author: Matthew J Cummings; Matthew R Baldwin; Darryl Abrams; Samuel D Jacobson; Benjamin J Meyer; Elizabeth M Balough; Justin G Aaron; Jan Claassen; LeRoy E Rabbani; Jonathan Hastie; Beth R Hochman; John Salazar-Schicchi; Natalie H Yip; Daniel Brodie; Max R O'Donnell
Title: Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study
  • Document date: 2020_4_20
    • ID: byh09alo_3
    Snippet: We reviewed electronic medical records, laboratory results, and radiographic findings for all admitted patients with critical illness and laboratory-confirmed COVID-19. Using a standardized case record form developed by the International Severe Acute Respiratory and Emerging Infection Consortium and World Health Organization (WHO), 11 we recorded data on demographics, known medical history and co-morbidities, illness onset and symptoms, vital sig.....
    Document: We reviewed electronic medical records, laboratory results, and radiographic findings for all admitted patients with critical illness and laboratory-confirmed COVID-19. Using a standardized case record form developed by the International Severe Acute Respiratory and Emerging Infection Consortium and World Health Organization (WHO), 11 we recorded data on demographics, known medical history and co-morbidities, illness onset and symptoms, vital signs and biochemical studies performed within 24 hours of diagnosis of acute respiratory failure. We also recorded concentrations of plasma-and serum-based biomarkers drawn at or within 48 hours of hospital admission, including C-reactive protein, d-dimer, ferritin, highsensitivity troponin, procalcitonin, and interleukin (IL)-6. We prospectively collected data on management interventions delivered during hospitalization including initiation and duration of mechanical ventilation, administration of advanced therapies for acute respiratory failure (neuromuscular blocking agents, inhaled pulmonary vasodilators, prone-positioning, and extracorporeal membrane oxygenation), vasopressor agents, renal replacement therapy, antibacterial, anti-viral, and immunomodulatory agents (interleukin-6-receptor antagonists and corticosteroids). All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory failure and biochemical study: 1
    • acute respiratory failure and co morbidity: 1, 2
    • acute respiratory failure and critical illness: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory failure and duration initiation: 1
    • acute respiratory failure and electronic medical record: 1
    • acute respiratory failure and extracorporeal membrane oxygenation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory failure and extracorporeal membrane oxygenation prone positioning: 1
    • acute respiratory failure diagnosis and critical illness: 1, 2
    • acute respiratory failure diagnosis and extracorporeal membrane oxygenation: 1
    • admit patient and extracorporeal membrane oxygenation: 1
    • advanced therapy and electronic medical record: 1
    • advanced therapy and extracorporeal membrane oxygenation: 1, 2, 3, 4, 5, 6
    • biochemical study and critical illness: 1, 2
    • biochemical study and duration initiation: 1
    • co morbidity and electronic medical record: 1
    • co morbidity and extracorporeal membrane oxygenation: 1
    • critical illness and electronic medical record: 1, 2, 3, 4, 5, 6
    • critical illness and extracorporeal membrane oxygenation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • critical illness and extracorporeal membrane oxygenation prone positioning: 1